Indeterminate melanoma cases reduced by three-quarters by diagnostic test

Share this content:

Malignant melanoma was differentiated from benign skin lesions with greater than 90% accuracy in a pivotal clinical utility study of the Myriad myPath Melanoma test. These results were presented at the 2014 College of American Pathologists annual meeting in Chicago, Illinois.

The study evaluated the impact of this diagnostic test on the diagnoses and treatment recommendations expert dermatopathologists made for their patients. The analysis included 687 cases of pigmented skin lesions submitted by 42 leading dermatopathologists in the United States. These melanoma experts were asked to document their diagnosis, level of confidence, any further testing, and recommendations for treatment both before and after receiving the myPath test results.

The results show that when the myPath Melanoma test score was provided to the dermatopathologists, they revised their treatment recommendations in 35% of cases. In addition, the myPath test score led to a 76% reduction in indeterminate diagnoses. These data strongly support the integration of myPath Melanoma into clinical practice to improve the diagnosis of melanoma and enhance patient care.

"This clinical utility study demonstrates how the myPath Melanoma test can be successfully incorporated into clinical care to improve the treatment of malignant melanoma," said Loren Clarke, MD, vice president of Medical Affairs at Myriad Genetic Laboratories. "Myriad myPath Melanoma provides objective information to answer an important clinical question: Does my patient have a melanoma that requires surgery or medical intervention or is the lesion a harmless mole that needs to be watched?"

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs